DDD I think you are getting too caught up in specifics. Remember...

DDD I think you are getting too caught up in specifics.

Remember this is a phase 1 trail only. And the first time the virus has been injected into humans.
People keep spouting off about deals coming soon $1 per share, $5 per share, $10 per share. Utter BS and totally not helpful. If there is a deal coming, it's after a registrational phase 2 trial at the earliest. If that is to happen it's Azercel, at the end of 2025 at the earliest. And there will almost certainly be a capital raising between now and then.

The MAST trial is only exploring two questions.
Is CF33 safe to give to humans?
And what is the optimal dosage?

Nothing else.

The fact we can see some efficiency from the first cut of data is positive but it is not the purpose of this study.

You keep escalating dosage until one of two things happen.
1) People start showing some toxicity, and getting sick / harm from the dosage.
2) The higher dosage is showing no further clinical benefit to the previous cohorts.

The fact the FDA signed of IT mono cohort 5 means.
CF33 is safe, and the patients are showing higher immune response in their bodies (keeping in mind it may yet still take months with pseudo progression to know that effect CF33 is having on their cancer burden).

So you go again into cohort 6.

Once the MAST trial closes they will know two important things. What is the optimal dosage for a phase 2 study. And what specific cancers they wish to go after.

We're lucky the FDA is allowing IMU to target any cancer in phase 1 MAST. But once we get to phase 2, IMU will need to get more specific with that it is trailing.

Each time a cohort is cleared, is a small positive step. The fact the company want to explore 1 X 10 to the 9th (cohort 6) is nothing but positive.

DYOR, IMO, not advice